Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

FOUNTAIN Stock Went Down By Over 9% So Far On Monday

Loading stream...

(VIANEWS) - Shares of FOUNTAIN (BEL 20: FOU.BR) slid 9.65% to €1.03 at 14:12 EST on Monday, after four successive sessions in a row of losses. BEL 20 is sliding 0.21% to €3,516.09, after five consecutive sessions in a row of losses. This seems, at the moment, a somewhat bearish trend exchanging session today.

About FOUNTAIN

Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in Europe. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was founded in 1972 and is based in Braine-l'Alleud, Belgium.

Earnings Per Share

As for profitability, FOUNTAIN has a trailing twelve months EPS of €-0.14.

Volume

Today's last reported volume for FOUNTAIN is 60 which is 72.72% below its average volume of 220.

More news about FOUNTAIN (FOU.BR).

Categories

stockMarket

Tags

FOU.BRStock PricePrice DownMarket Session NowStock Price DownStock Market NowMarket SessionFOUNTAINStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com